• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Shire: Statement re Proposal from Takeda Pharmaceutical Company

    Gabrielle Lakusta
    Apr. 23, 2018 08:40AM PST
    Pharmaceutical Investing

    Shire (NASDAQ:SHPG) notes the announcement made by Takeda (TYO:4502) and confirms it has received a fourth proposal on 20 April 2018 regarding a possible offer for the Company. As quoted in the press release: The Fourth Proposal comprises £26 per share in new Takeda shares, to be listed in Japan and in the US through …

    Shire (NASDAQ:SHPG) notes the announcement made by Takeda (TYO:4502) and confirms it has received a fourth proposal on 20 April 2018 regarding a possible offer for the Company.

    As quoted in the press release:

    The Fourth Proposal comprises £26 per share in new Takeda shares, to be listed in Japan and in the US through an ADR listing, and £21 per share in cash, representing a potential value of £47 per share and approximately £44 billion for the total issued and to be issued share capital of the Company. Based on Takeda’s current market capitalisation, Shire shareholders would own approximately 49 per cent. of the enlarged Takeda.

    The Board of Shire is considering its position with respect to the Fourth Proposal and will issue a further announcement in due course.

    This announcement is made without the consent of Takeda.

    Click here to read the full press release.

    pharmaceutical investing
    The Conversation (0)

    Go Deeper

    AI Powered

    Pfizer Declares Fourth-Quarter 2025 Dividend

    Scientist with petri dish.

    Pharma Market Forecast: Top Trends for Pharma in 2025

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA

    Invion Limited

    IVX:AU

    Principal Technologies

    PTEC:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES